Phase 2 N=80 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
Phase 2 N=204 To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change of Corneal Fluorescein Staining of the Inferior Cornea Region. — -1.00; -0.78; -0.78 units on a scale (Likert)
Phase 3 N=455 Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Conjunctival Staining — -1.9; -1.8; -1.2 score on a scale
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
Phase 3 N=176 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Atopic Conjunctivitis
Primary: Percentage of Treatment Responders — 21.3; 17.2 Percentage of Patients
Phase 3 N=258 An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Adverse Events — 68; 81 Count of participants
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
Phase 3 N=350 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Dry Eye Disease With Severe Keratitis
Primary: The Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at Each Visit…
Phase 3 N=901 Safety and Efficacy of KPI-121 in Subjects With DED
Kerato Conjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) — -13.58; -8.91 score on a scale
N/A N=781 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Ocular Surface Disease Index (OSDI) Total Score at Baseline — 40.3 Scores on a Scale
Phase 4 N=40 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
Dry Eye Syndromes
Primary: Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye — 7.29; -1.96 Scores on a Scale
Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
Phase 2 N=150 Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Bulbar Conjunctival Hyperemia — 1.22; 1.36 score on a scale
Phase 3 N=905 Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15) — -0.3812; -0.2371 score on a scale
N/A N=286 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis
Dry Eye Syndromes · Rheumatoid Arthritis
Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants
N/A N=400 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy
Dry Eye Syndromes
Primary: Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale — 65.0; 29.0; 4.2; 1.8 Percentage of Patients
Phase 3 N=915 Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15) — -0.4049; -0.1574 score on a scale
Phase 2 N=201 Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (tCFS) at Day 60 — -2.04; -1.65; -2.15; -1.54 tCFS score on a scale of 0 - 20
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Phase 4 N=39 Nasal Spray Study in Sjogren's Dry Eye Disease
Sjogren's Syndrome · Dry Eye
Primary: Mean Change in Cornea Staining — -1.78 units on a scale
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
Phase 4 N=82 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline in Global Ocular Staining Score at Day 35 — 5.4; 5.9; -1.8; -1.8 Number on a scale (score)
Phase 4 N=134 Effect of Cequa™ in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Mean Change in Baseline in Total Corneal Fluoroscein Staining Score — -3.1 score on a scale — p=<0.0001
Phase 4 N=17 Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
Keratitis
Primary: Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3. — -0.7028 Spearman's…
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm